Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Patient will be identified by surgeon and consented by member of the research team
- Patient will be randomized to one of three groups on the day of surgery
- Following securement of the endotracheal tube, the study medication will be administered over 10 minutes via an IV infusion pump.
- The subject will receive ketamine, ketamine plus magnesium or a placebo.
- Following surgery, the patient will be taken to the post anesthesia care unit (PACU) and set up with standard ASA monitoring as well as end-tidal CO2 via nasal cannula. A hydromorphone patient controlled analgesia (PCA) pump will be set-up by nursing and given to the patient. Standard dosing of 0.2 mg bolus, every 6 minutes with a maximum 2 mg will be the starting dose as is standard for these patients post-operatively.
Primary outcome will be the total amount of hydromorphone used in the first 24 hours post-operatively.
.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Milton S.Hershey Medical center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects undergoing laparoscopic sleeve gastrectomy
- Consenting adults age 18-80
- ASA II to ASA III
- Ability to understand and use a PCA
- Required to be hospitalized for at least 24 hours post-op
Exclusion Criteria:
- Patient refusal
- Chronic opiate use (daily opiate use for >3 months)
- Chronic Kidney disease (Creatinine>2)
- Known allergy or adverse effect of ketamine, magnesium or hydromorphone
- Patients with documented psychiatry (Maniac or MDP) history
- Patient unable to give informed consent
- Patient with limited or no English fluency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Ketamine
Ketamine: 0.5 mg/kg IV dose
|
Ketamine infusion plus placebo infusion of normal saline
2 placebo infusions
Other Names:
|
|
Active Comparator: Ketamine plus magnesium
Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
|
Ketamine plus magnesium infusion
|
|
Placebo Comparator: Placebo
Placebo (normal saline)
|
2 placebo infusions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Hydromorphone Use
Time Frame: During surgery and 24 hours post-op
|
Total hydromorphone use in 1st 24 hours post-operatively.
|
During surgery and 24 hours post-op
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Scores Using Verbal Analogue Scale (VAS)
Time Frame: Preoperatively and the 1st 24 hours post-op
|
Pain scores using VAS scale will be recorded pre-operatively, in the PACU, and every 4 hours until 24 hours post-op.
The VAS is a 10 point scale, where 0 = no pain and 10 = the worst pain a subject has ever felt.
The highest value 10, indicates an extreme self reported level of pain.
|
Preoperatively and the 1st 24 hours post-op
|
|
Intraoperative Minimum Alveolar Concentration (MAC) of Desflurane
Time Frame: Intraoperative period
|
The average MAC concentration of desflurane will be recorded during the intraoperative period.
The Minimum Alveolar Concentration (MAC) of an inhaled anesthetic is the alveolar (or end-expiratory) concentration at which 50% of patients will not show a motor response to a standardized surgical incision.
|
Intraoperative period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sanjib Adhikary, MB, BS,MD, PSHMC College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- STUDY00001623
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.